GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Shares Outstanding (EOP)

Gan & Lee Pharmaceuticals Co (SHSE:603087) Shares Outstanding (EOP) : 601 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Gan & Lee Pharmaceuticals Co's shares outstanding for the quarter that ended in Mar. 2025 was 601 Mil.

Gan & Lee Pharmaceuticals Co's quarterly shares outstanding stayed the same from Dec. 2024 (601 Mil) to Mar. 2025 (601 Mil).

Gan & Lee Pharmaceuticals Co's annual shares outstanding increased from Dec. 2023 (594 Mil) to Dec. 2024 (601 Mil). It means Gan & Lee Pharmaceuticals Co issued new shares from Dec. 2023 to Dec. 2024 .


Gan & Lee Pharmaceuticals Co Shares Outstanding (EOP) Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co Shares Outstanding (EOP) Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 561.54 561.54 565.65 594.16 601.07

Gan & Lee Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 594.16 601.20 601.07 601.07 601.07

Competitive Comparison of Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP)

For the Medical Instruments & Supplies subindustry, Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP) falls into.


;
;

Gan & Lee Pharmaceuticals Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Gan & Lee Pharmaceuticals Co  (SHSE:603087) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Gan & Lee Pharmaceuticals Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Gan & Lee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines